MTOR and renal cell carcinoma: Considering acquired resistance usually develops with single‐agent treatment,[66] and currently various targeted therapies have been approved in treating RCC patients in clinic including tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, axitinib, and others), HIF inhibitors (belzutifan) and mTOR inhibitors (temsirolimus and everolimus), we next examined if 2‐BP exerts any synergistic effects with clinically approved agents.